O	0	10	Modulation	Modulation	NN	B-NP
O	11	13	of	of	IN	B-PP
O	14	26	angiogenesis	angiogenesis	NN	B-NP
O	27	30	and	and	CC	I-NP
O	31	44	progelatinase	progelatinase	NN	I-NP
O	45	46	a	a	DT	O
O	47	49	by	by	IN	B-PP
O	50	58	thrombin	thrombin	NN	B-NP
O	59	67	receptor	receptor	NN	I-NP
O	68	76	mimetics	mimetic	NNS	I-NP
O	77	80	and	and	CC	I-NP
O	81	92	antagonists	antagonist	NNS	I-NP
O	92	93	.	.	.	O

O	94	97	The	The	DT	B-NP
O	98	108	angiogenic	angiogenic	JJ	I-NP
O	109	115	action	action	NN	I-NP
O	116	118	of	of	IN	B-PP
O	119	127	thrombin	thrombin	NN	B-NP
O	128	131	has	have	VBZ	B-VP
O	132	136	been	be	VBN	I-VP
O	137	142	shown	show	VBN	I-VP
O	143	145	to	to	TO	I-VP
O	146	148	be	be	VB	I-VP
O	149	157	mediated	mediate	VBN	I-VP
O	158	160	by	by	IN	B-PP
O	161	171	activation	activation	NN	B-NP
O	172	174	of	of	IN	B-PP
O	175	178	the	the	DT	B-NP
O	179	187	thrombin	thrombin	NN	I-NP
O	188	196	receptor	receptor	NN	I-NP
O	196	197	.	.	.	O

O	198	200	In	In	IN	B-PP
O	201	205	this	this	DT	B-NP
O	206	212	report	report	NN	I-NP
O	213	215	we	we	PRP	B-NP
O	216	223	studied	study	VBD	B-VP
O	224	227	the	the	DT	B-NP
O	228	235	effects	effect	NNS	I-NP
O	236	238	of	of	IN	B-PP
O	239	244	SFLLR	SFLLR	NN	B-NP
O	244	245	,	,	,	O
O	246	248	an	an	DT	B-NP
O	249	256	agonist	agonist	NN	I-NP
O	257	259	of	of	IN	B-PP
O	260	263	the	the	DT	B-NP
O	264	273	activated	activate	VBN	I-NP
O	274	282	thrombin	thrombin	NN	I-NP
O	283	291	receptor	receptor	NN	I-NP
O	292	295	and	and	CC	I-NP
O	296	304	thrombin	thrombin	NN	I-NP
O	305	313	receptor	receptor	NN	I-NP
O	314	321	peptide	peptide	NN	I-NP
O	322	325	and	and	CC	O
O	326	329	non	non	JJ	B-NP
O	330	337	peptide	peptide	NN	I-NP
O	338	349	antagonists	antagonist	NNS	I-NP
O	350	352	on	on	IN	B-PP
O	353	365	angiogenesis	angiogenesis	NN	B-NP
O	366	368	in	in	IN	B-PP
O	369	372	the	the	DT	B-NP
O	373	378	chick	chick	NN	I-NP
B-Multi-tissue_structure	379	394	chorioallantoic	chorioallantoic	JJ	I-NP
I-Multi-tissue_structure	395	403	membrane	membrane	NN	I-NP
O	404	405	(	(	(	O
B-Multi-tissue_structure	405	408	CAM	CAM	NN	B-NP
O	408	409	)	)	)	O
O	410	416	system	system	NN	B-NP
O	416	417	.	.	.	O

O	418	420	As	As	IN	B-SBAR
O	421	432	antagonists	antagonist	NNS	B-NP
O	433	437	were	be	VBD	B-VP
O	438	442	used	use	VBN	I-VP
O	443	446	the	the	DT	B-NP
O	447	457	tripeptide	tripeptide	NN	I-NP
O	458	461	FPR	FPR	NN	I-NP
O	462	465	and	and	CC	O
O	466	469	non	non	AFX	O
O	469	470	-	-	HYPH	O
O	470	477	peptide	peptide	NN	B-NP
O	478	479	1	1	CD	I-NP
O	479	480	,	,	,	I-NP
O	480	481	4	4	CD	I-NP
O	481	482	-	-	HYPH	O
O	482	495	disubstituted	disubstitute	VBN	B-NP
O	496	506	piperazine	piperazine	NN	I-NP
O	507	518	derivatives	derivative	NNS	I-NP
O	518	519	.	.	.	O

O	520	523	The	The	DT	B-NP
O	524	536	pentapeptide	pentapeptide	NN	I-NP
O	537	542	SFLLR	SFLLR	NN	I-NP
O	542	543	,	,	,	O
O	544	548	like	like	IN	B-PP
O	549	557	thrombin	thrombin	NN	B-NP
O	557	558	,	,	,	O
O	559	565	caused	cause	VBD	B-VP
O	566	567	a	a	DT	B-NP
O	568	574	marked	marked	JJ	I-NP
O	575	586	stimulation	stimulation	NN	I-NP
O	587	589	of	of	IN	B-PP
O	590	602	angiogenesis	angiogenesis	NN	B-NP
O	603	605	in	in	IN	B-PP
O	606	609	the	the	DT	B-NP
B-Multi-tissue_structure	610	613	CAM	CAM	NN	I-NP
O	613	614	.	.	.	O

O	615	618	FPR	FPR	NN	B-NP
O	619	622	and	and	CC	O
O	623	626	the	the	DT	B-NP
O	627	637	piperazine	piperazine	NN	I-NP
O	638	649	derivatives	derivative	NNS	I-NP
O	650	656	caused	cause	VBD	B-VP
O	657	668	suppression	suppression	NN	B-NP
O	669	671	of	of	IN	B-PP
O	672	684	angiogenesis	angiogenesis	NN	B-NP
O	685	688	and	and	CC	B-PP
O	689	691	in	in	IN	B-PP
O	692	703	combination	combination	NN	B-NP
O	704	708	with	with	IN	B-PP
O	709	717	thrombin	thrombin	NN	B-NP
O	718	729	antagonized	antagonize	VBD	B-VP
O	730	733	its	its	PRP$	B-NP
O	734	744	angiogenic	angiogenic	JJ	I-NP
O	745	751	effect	effect	NN	I-NP
O	751	752	.	.	.	O

O	753	761	Thrombin	Thrombin	NN	B-NP
O	762	765	and	and	CC	I-NP
O	766	771	SFLLR	SFLLR	NN	I-NP
O	772	781	activated	activate	VBD	B-VP
O	782	795	progelatinase	progelatinase	NN	B-NP
O	796	797	A	A	NN	I-NP
O	798	799	(	(	(	O
O	799	802	MMP	MMP	NN	B-NP
O	802	803	-	-	HYPH	O
O	803	804	2	2	CD	B-NP
O	804	805	)	)	)	O
O	806	808	in	in	IN	B-PP
O	809	812	the	the	DT	B-NP
O	813	820	culture	culture	NN	I-NP
O	821	827	medium	medium	NN	I-NP
O	828	830	of	of	IN	B-PP
B-Cell	831	836	human	human	JJ	B-NP
I-Cell	837	846	umbilical	umbilical	JJ	I-NP
I-Cell	847	851	cord	cord	NN	I-NP
I-Cell	852	863	endothelial	endothelial	JJ	I-NP
I-Cell	864	869	cells	cell	NNS	I-NP
O	870	871	(	(	(	O
B-Cell	871	877	HUVECs	HUVEC	NNS	B-NP
O	877	878	)	)	)	O
O	878	879	.	.	.	O

O	880	883	MMP	MMP	NN	B-NP
O	883	884	-	-	HYPH	O
O	884	885	2	2	CD	B-NP
O	886	888	is	be	VBZ	B-VP
O	889	897	involved	involve	VBN	I-VP
O	898	900	in	in	IN	B-PP
O	901	904	the	the	DT	B-NP
O	905	910	early	early	JJ	I-NP
O	911	916	steps	step	NNS	I-NP
O	917	919	of	of	IN	B-PP
O	920	932	angiogenesis	angiogenesis	NN	B-NP
O	933	940	leading	lead	VBG	B-VP
O	941	943	to	to	TO	B-PP
O	944	949	local	local	JJ	B-NP
O	950	961	dissolution	dissolution	NN	I-NP
O	962	964	of	of	IN	B-PP
B-Cellular_component	965	973	basement	basement	NN	B-NP
I-Cellular_component	974	982	membrane	membrane	NN	I-NP
O	983	991	collagen	collagen	NN	I-NP
O	992	995	and	and	CC	I-NP
O	996	1005	migration	migration	NN	I-NP
O	1006	1008	of	of	IN	B-PP
O	1009	1012	the	the	DT	B-NP
O	1013	1022	activated	activate	VBN	I-NP
B-Cell	1023	1034	endothelial	endothelial	JJ	I-NP
I-Cell	1035	1040	cells	cell	NNS	I-NP
O	1040	1041	.	.	.	O

O	1042	1045	FPR	FPR	NN	B-NP
O	1046	1049	and	and	CC	O
O	1050	1053	the	the	DT	B-NP
O	1054	1064	piperazine	piperazine	NN	I-NP
O	1065	1076	derivatives	derivative	NNS	I-NP
O	1077	1086	inhibited	inhibit	VBD	B-VP
O	1087	1090	the	the	DT	B-NP
O	1091	1101	activation	activation	NN	I-NP
O	1102	1104	of	of	IN	B-PP
O	1105	1109	this	this	DT	B-NP
O	1110	1116	enzyme	enzyme	NN	I-NP
O	1116	1117	.	.	.	O

O	1118	1122	They	They	PRP	B-NP
O	1123	1127	also	also	RB	B-ADVP
O	1128	1139	antagonised	antagonise	VBD	B-VP
O	1140	1143	the	the	DT	B-NP
O	1144	1151	effects	effect	NNS	I-NP
O	1152	1154	of	of	IN	B-PP
O	1155	1159	both	both	CC	O
O	1160	1168	thrombin	thrombin	NN	B-NP
O	1169	1172	and	and	CC	O
O	1173	1178	SFLLR	SFLLR	NN	B-NP
O	1179	1181	on	on	IN	B-PP
O	1182	1185	MMP	MMP	NN	B-NP
O	1185	1186	-	-	HYPH	O
O	1186	1187	2	2	CD	B-NP
O	1188	1198	activation	activation	NN	I-NP
O	1198	1199	.	.	.	O

O	1200	1205	These	These	DT	B-NP
O	1206	1213	results	result	NNS	I-NP
O	1214	1221	suggest	suggest	VBP	B-VP
O	1222	1226	that	that	IN	B-SBAR
O	1227	1230	non	non	AFX	B-NP
O	1230	1231	-	-	HYPH	I-NP
O	1231	1243	thrombogenic	thrombogenic	JJ	I-NP
O	1244	1252	agonists	agonist	NNS	I-NP
O	1253	1255	or	or	CC	I-NP
O	1256	1267	antagonists	antagonist	NNS	I-NP
O	1268	1270	of	of	IN	B-PP
O	1271	1274	the	the	DT	B-NP
O	1275	1284	activated	activate	VBN	I-NP
O	1285	1293	thrombin	thrombin	NN	I-NP
O	1294	1302	receptor	receptor	NN	I-NP
O	1303	1306	can	can	MD	B-VP
O	1307	1309	be	be	VB	I-VP
O	1310	1314	used	use	VBN	I-VP
O	1315	1317	as	as	IN	B-PP
O	1318	1328	modulators	modulator	NNS	B-NP
O	1329	1331	of	of	IN	B-PP
O	1332	1344	angiogenesis	angiogenesis	NN	B-NP
O	1344	1345	.	.	.	O

